Tigecycline Antibodies

Target Information

Tigecycline is a semisynthetic antibiotic belonging to the glycylcycline class, developed to treat polymicrobial infections caused by multidrug-resistant Gram-positive and Gram-negative pathogens. It is designed to evade tetracycline resistance mechanisms, such as ribosomal protection and active drug efflux. Tigecycline functions by binding to the 30S ribosomal subunit, inhibiting protein synthesis in bacteria, which makes it effective against a wide range of bacterial infections. Despite its efficacy, the emergence of high-level tigecycline resistance, particularly mediated by plasmid-encoded genes like tet(X), poses a significant challenge to its clinical use. Strategies to overcome resistance include combining tigecycline with adjuvants like curcumin, which can reverse resistance mechanisms. Tigecycline is administered intravenously and is considered a last-resort antibiotic due to its broad-spectrum activity and ability to overcome resistance mechanisms.